Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study

Summary

The Ranibizumab in Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration (RIP) Study is a prospective, multicenter, uncontrolled, interventional phase 2 clinical trial that investigates the effect of fixed monthly intravitreal injections of ranibizumab (Lucentis, Novartis Pharma, Germany) on visual acuity and retinal morphology over a study period of 12 months in 30 patients.

Timeline

Start

2013-02

Primary completion

2016-03

Completion

2016-03

Drugs

Indications